Is KMDA above its 150-day moving average?

KMDA is currently above its 150-day moving average by 1.04%. The MA150 sits at $7.73.

What is KMDA's RSI right now?

KMDA's 14-period RSI is 42.9. This is in a neutral zone (30–70).

Is KMDA's MACD bullish or bearish?

KMDA's MACD histogram reads -0.0062. A negative histogram means short-term momentum is leaning bearish.

How are KMDA's technical signals calculated?

Scanance computes KMDA's technicals daily after market close from end-of-day OHLCV data. MA150 and MA200 are simple moving averages. RSI uses Wilder's 14-period smoothing. MACD uses 12/26/9 exponential moving averages. Volume ratio compares current volume to the 20-day average.

Scanance does not provide investment advice. The technical readouts on this page are pattern matches against deterministic indicator rules — they are not buy or sell recommendations. Always do your own research and consider consulting a licensed financial professional before making any trade.

KM

Kamada Ltd.

KMDAHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic

PriceMA150MA200

Loading chart…

End-of-day data · ScananceOpen live chart on TradingView ↗

Indicator snapshot · Today

Premium

Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →

Financials · Annual

Revenue

$180.5M

+12.1% YoY

Net Income

$20.2M

+39.7% YoY

EBITDA

$39.2M

+41.2% YoY

Free Cash Flow

$10.5M

Scan Results

Daily timeframe

DateIndicatorDetails

About Kamada Ltd.

Part of the healthcare sector, Kamada Ltd. (KMDA) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $451.5M market cap, placing it firmly in the small-cap category. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.

Key stats

Market Cap$451.5M

P/E (TTM)22.31

Fwd P/E12.73

EPS$0.35

52W Change+13.2%

Dividend Yield3.20%

ROE8.0%

Analysis

The balance sheet looks solid with $73.1M in cash comfortably exceeding the $11.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $10.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 8.0%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $129.3M (2022) to $180.5M (2025), reflecting a 40% increase over the period.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kamada Ltd.'s trajectory.

Links

Company website ↗

Kamada Ltd.

News & analytics is part of Premium.

Technical readouts are part of Premium.